Business Overview: Myomo, Inc. (NYSE American: MYO)

---

Executive Summary

Myomo, Inc. is a wearable medical robotics company that develops and sells the MyoPro, a custom-fabricated, myoelectric upper-limb orthosis for people with neuromuscular conditions such as stroke, brachial plexus injury, and spinal cord injury. The device uses non-invasive EMG sensors to detect a user's own weak muscle signals and drives motors that move the affected arm, with the user actively initiating each movement.

Headquartered in Boston, Massachusetts, Myomo is a small but category-defining company: by its own characterization in its 10-K, the MyoPro is "the only device commercially available in the United States" that restores functional arm movement this way. Fiscal 2025 revenue grew 26% year-over-year to approximately $40.9 million, reflecting faster reimbursement cycle times for a product that remains largely unchallenged in its specific clinical niche.

---

1. Core Business Model & How They Work

Myomo operates as a single business segment and earns revenue through two channels: direct billing to insurers, and wholesale sales to orthotics and prosthetics (O&P) providers who add their own clinical fitting services.

[ Patient Evaluation & Custom Fitting ] ➡️ [ MyoPro Manufactured (Burlington, MA) ] ➡️ [ Delivered Direct or via O&P Provider ] ➡️ [ Billed to Insurer under HCPCS L8701/L8702 ] ➡️ [ Reimbursement Collected ]

Key Operational Drivers

1. Direct billing model: Direct-to-insurer billing was 74% of product revenue in 2025 (down from 78% in 2024), as the company increasingly shifts volume toward O&P channel partners, which it expects to grow further.
2. Reimbursement-driven pricing: The MyoPro is billed under HCPCS codes L8701 (Motion W, ~$34,970) and L8702 (Motion G, ~$68,800), effective January 1, 2026; Motion G alone generated 96% of 2025 product revenue.
3. Pipeline-driven growth: 1,528 patients were in the reimbursement pipeline at year-end 2025 (up 10%), while units in backlog fell 27% to 199 — evidence that faster processing, not just more patients, drove 2025's revenue growth.
4. IP-protected product: 35 issued patents and 14 pending applications (expirations 2027–2042) protect the core EMG-sensing and actuation technology.
5. International and VA expansion: Sales also reach the U.S. Department of Veterans Affairs and international markets including Germany, the UK, Denmark, Italy, and Australia.

---

2. Product Portfolio

---

3. Competitive Landscape

Myomo faces indirect competition from alternative treatment approaches rather than a direct head-to-head product rival in its core reimbursement category.

         UPPER-LIMB NEUROREHAB POSITIONING
   High │
        │                      [Myomo MyoPro]
  C     │                    (Only reimbursable
  L     │                     powered device for
  I     │                     this specific use)
  N     │
  I     │   [Exoskeletons: Lifeward,      [Standard rehab
  C     │    Ekso Bionics, Cyberdyne]      therapy, non-
  A     │                                  powered braces]
  L     │   [Implantable VNS: MicroTransponder]
   Low  │
        └──────────────────────────────────►
         Low      REIMBURSEMENT CLARITY      High

• Standard rehabilitation therapy and non-powered braces: the conventional standard of care, lower cost but without the MyoPro's active, EMG-driven movement restoration.
• Exoskeleton suits (Lifeward, Ekso Bionics, Cyberdyne): generally designed for gait/lower-body or broader rehabilitation use cases, with different reimbursement pathways.
• Implantable vagus nerve stimulators (MicroTransponder): an invasive alternative approach to motor recovery.
• New O&P entrants (Neurolutions, Vincent Systems, HKK Bionics): earlier-stage competitors beginning to target similar upper-limb orthotic use cases.

---

4. Strategic Strengths & Risks

Strengths

• Category-defining, patent-protected product: 35 issued patents and a clinically unique mechanism create real barriers to direct replication.
• Established reimbursement pathway: Dedicated HCPCS codes (L8701/L8702) with defined CMS fee schedules reduce one of medtech's hardest commercialization hurdles.
• Accelerating revenue growth: 26% revenue growth in 2025 driven by faster cycle times, not just unit volume, suggests improving operational execution.
• Growing payer coverage: Contracts covering about 35 million lives with Medicare Advantage and commercial payers signed in 2025.

Risks

• Continued net losses: Net loss widened to approximately $15.6 million in 2025; the company has not yet achieved sustained operating cash flow breakeven.
• Reimbursement dependency and case-by-case approval: Non-Medicare payers generally require pre-authorization decided case-by-case, and signed payer contracts "do not guarantee reimbursement," per the 10-K.
• Small scale, concentrated manufacturing: A single Burlington, MA facility with 120 units/month capacity creates execution and single-site risk.
• Rising competitive attention: New O&P entrants (Neurolutions, Vincent Systems, HKK Bionics) signal the niche is starting to attract competition.
• Capital needs: Management acknowledges additional capital may be required if the company does not return to quarterly cash flow breakeven.

---

5. Financial Overview

---

6. Summary Conclusion

Myomo holds a genuinely differentiated, patent-protected position as the only reimbursable powered device restoring arm movement for a specific population of partially paralyzed patients, and its 2025 results show that faster reimbursement processing — not just a larger sales pipeline — is now translating into real revenue growth. The company's central risk is financial, not competitive: it remains unprofitable, dependent on continued payer cooperation and case-by-case authorization decisions it cannot fully control, and will need to sustain its current growth rate to reach cash flow breakeven before new O&P entrants have time to erode its currently near-exclusive clinical position.